These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

449 related articles for article (PubMed ID: 18288997)

  • 1. From single- to multi-target drugs in cancer therapy: when aspecificity becomes an advantage.
    Petrelli A; Giordano S
    Curr Med Chem; 2008; 15(5):422-32. PubMed ID: 18288997
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of anti-angiogenesis agents in treating NSCLC: focus on bevacizumab and VEGFR tyrosine kinase inhibitors.
    Cabebe E; Wakelee H
    Curr Treat Options Oncol; 2007 Feb; 8(1):15-27. PubMed ID: 17634832
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Indications and current development of new targeted therapies in pediatric oncology].
    Leblond P; Geoerger B
    Bull Cancer; 2011 May; 98(5):527-39. PubMed ID: 21596652
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel molecular targeted therapies for refractory thyroid cancer.
    Perez CA; Santos ES; Arango BA; Raez LE; Cohen EE
    Head Neck; 2012 May; 34(5):736-45. PubMed ID: 21544895
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of the tyrosine kinase inhibitors (sunitinib, sorafenib, dasatinib, and imatinib) on blood glucose levels in diabetic and nondiabetic patients in general clinical practice.
    Agostino NM; Chinchilli VM; Lynch CJ; Koszyk-Szewczyk A; Gingrich R; Sivik J; Drabick JJ
    J Oncol Pharm Pract; 2011 Sep; 17(3):197-202. PubMed ID: 20685771
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted therapy in advanced non-small-cell lung cancer.
    Gettinger S
    Semin Respir Crit Care Med; 2008 Jun; 29(3):291-301. PubMed ID: 18506667
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Bemusement and strategy on the efficacy of clinical application of targeted anticancer drugs].
    Wang ZY
    Zhonghua Zhong Liu Za Zhi; 2009 Sep; 31(9):641-5. PubMed ID: 20021856
    [No Abstract]   [Full Text] [Related]  

  • 8. Differential drug class-specific metastatic effects following treatment with a panel of angiogenesis inhibitors.
    Chung AS; Kowanetz M; Wu X; Zhuang G; Ngu H; Finkle D; Komuves L; Peale F; Ferrara N
    J Pathol; 2012 Aug; 227(4):404-16. PubMed ID: 22611017
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted therapies in the treatment of advanced/metastatic NSCLC.
    Pallis AG; Serfass L; Dziadziusko R; van Meerbeeck JP; Fennell D; Lacombe D; Welch J; Gridelli C
    Eur J Cancer; 2009 Sep; 45(14):2473-87. PubMed ID: 19596191
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rationale and clinical results of multi-target treatments in oncology.
    Sartore-Bianchi A; Ricotta R; Cerea G; Maugeri MR; Siena S
    Int J Biol Markers; 2007; 22(1 Suppl 4):S77-87. PubMed ID: 17520585
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of receptor tyrosine kinases in gastric cancer: new targets for a selective therapy.
    Becker JC; Muller-Tidow C; Serve H; Domschke W; Pohle T
    World J Gastroenterol; 2006 Jun; 12(21):3297-305. PubMed ID: 16733844
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic Drug Monitoring of the new targeted anticancer agents imatinib, nilotinib, dasatinib, sunitinib, sorafenib and lapatinib by LC tandem mass spectrometry.
    Haouala A; Zanolari B; Rochat B; Montemurro M; Zaman K; Duchosal MA; Ris HB; Leyvraz S; Widmer N; Decosterd LA
    J Chromatogr B Analyt Technol Biomed Life Sci; 2009 Jul; 877(22):1982-96. PubMed ID: 19505856
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Gastrointestinal stromal tumors: molecular aspects and therapeutic implications].
    Italiano A; Bui B
    Bull Cancer; 2008 Jan; 95(1):107-16. PubMed ID: 18230576
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protein kinases as drug targets in cancer.
    Arslan MA; Kutuk O; Basaga H
    Curr Cancer Drug Targets; 2006 Nov; 6(7):623-34. PubMed ID: 17100568
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In pursuit of new anti-angiogenic therapies for cancer treatment.
    Cai J; Han S; Qing R; Liao D; Law B; Boulton ME
    Front Biosci (Landmark Ed); 2011 Jan; 16(3):803-14. PubMed ID: 21196204
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Antineoplastic agents targeting tyrosine kinases].
    Guren TK; Christoffersen T; Thoresen GH; Wisløff F; Dajani O; Tveit KM
    Tidsskr Nor Laegeforen; 2005 Nov; 125(22):3115-9. PubMed ID: 16299568
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Lung cancer].
    Fischer B; Buhl R
    Med Klin (Munich); 2008 May; 103(5):311-20. PubMed ID: 18484217
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted therapy for metastatic renal cell carcinoma.
    Patel PH; Chaganti RS; Motzer RJ
    Br J Cancer; 2006 Mar; 94(5):614-9. PubMed ID: 16465192
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early clinical studies of novel therapies for thyroid cancers.
    Sherman SI
    Endocrinol Metab Clin North Am; 2008 Jun; 37(2):511-24, xi. PubMed ID: 18502340
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [KIT and KIT: from biology to clinical use].
    Curtit E; Mansi L; Viel E; Dobi E; Chaigneau L; Nguyen T; Pivot X; Blay JY; Kalbacher E
    Bull Cancer; 2012 Feb; 99(2):191-7. PubMed ID: 21669561
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.